ClinicalTrials.gg
Active, not recruitingNCT06864793Updated Feb 17, 2026

Study on the Pharmacokinetics and Safety of QL1012D and Gonal-F® in Healthy Female Volunteers

A Phase 1 interventional study of QL1012D and Gonal-F® in Infertility, Female, sponsored by Qilu Pharmaceutical Co., Ltd.. Active, not recruiting at 1 site in China. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies in Infertility, Female with a site in China — 18 open to participants now, 20 under way, 1 of them phase 3. Infertility, Female · China.

Planned enrollment
45th of 51
48 · median 178
Started
2025
with 6 others
Phase 1
8 of 58
1 open now
Primary completion
2026-02
later than 6 of 19 live
Registered
51st of 58
by date

Among the 58 studies in Infertility, Female with a site in China, this one is the 45th largest by planned enrollment of the 51 interventional ones that give a count, is one of 7 that started in 2025, is one of 8 in phase 1, reaches primary completion later than 6 of the 19 other live ones, and was the 51st registered.

Infertility, Female

552 studies on the registry are indexed under Infertility, Female; 135 are open to participants now.

Browse Infertility, Female studies →

Open to participants now

18 of the 58 studies in Infertility, Female with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 90 Infertility, Female studies recruiting now, 11 (12%) set no upper age limit and 79 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Infertility, Female with a site in China, or all of them as a file.
02

Study summary

The goal of this Interventional study is to Compare the Pharmacokinetics and Safety of Recombinant Human Follicle Stimulating Hormone Injection (QL1012D) and Gonal-F® in Healthy Female Volunteers. It aims to evaluate the bioequivalence of recombinant human follicle stimulating hormone injection (QL1012D) and Gonal-F®, both given subcutaneously.

03

Conditions studied

  • Infertility, Female

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female, Age between 18 to 45 years (inclusive).
  • (BMI) of ≥18 and ≤28 kg/m2, body weight ≥45 kg.
  • With a history of sexual activity
  • Regular menstruation cycle (25 to 35 days, inclusive).
  • Normal sex hormone levels, or abnormalities deemed clinically insignificant by the investigator.
  • Reached the standard within the time window after receiving the down-regulated drug.
  • Agreed to take effective measures during and 6 months after the end of the study period.
  • Willing to participate in this clinical trial, understanding the study procedures, and able to provide written .

Exclusion criteria

Exclusion Criteria:

  • History of ovarian hyperstimulation syndrome, or polycystic ovary syndrome, or ovarian enlargement or cysts not caused by polycystic ovary syndrome, or primary ovarian failure; history of hypothalamic or pituitary tumors; history of ; History of thrombosis; or other diseases that considered to influence the study by the investigator.
  • Unexplained reproductive tract bleeding.
  • Thin-layer cytology examination deemed by the investigator.
  • Vital signs, physical examination, 12-lead , or laboratory examination deemed clinically significant by the investigator with.
  • Pregnancy or lactation period, or positive human chorionic gonadotropin (HCG) examination.
  • Known to be allergic to follicle-stimulating hormone (FSH), or gonadotropin-releasing hormone agonists (GnRH-a) or their analogs
  • Consume strong coffee or tea daily
  • Historic abuse of alcoholic beverages
  • Smoke ≥5 cigarettes per day within 3 months prior to the study
  • History of drug abuse
  • Unsuitable for participation by the investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Arm A QL1012D

    Drug: QL1012D

  • Active comparator
    Arm B Gonal-F®

    Drug: Gonal-F®

Interventions

  • A single Subcutaneous injection, 225IU

    Also known as: Follitropin alfa

  • A single Subcutaneous injection, 225IU

    Also known as: Follitropin alfa

06

What researchers measure

Primary outcomes

  1. Cmax (maximum plasma concentration)

    Maxmum observed serum concentration (Cmax) of QL1012D&Gonal-f® in healthy Chinese female subjects.

    Time frame: First Period: From pre-dose (0 hour) to 216 hours post-dose on Day 1. Second Period: From pre-dose (0 hour) to 216 hours post-dose on Day 11

  2. AUC (area under the curve)

    Adjusted geometric means of area under the serum concentration-time curve (AUC) of QL1012D&Gonal-f® in healthy Chinese female subjects.

    Time frame: First Period: From pre-dose (0 hour) to 216 hours post-dose on Day 1. Second Period: From pre-dose (0 hour) to 216 hours post-dose on Day 11

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Feb 2026, 9 months.

Of 15 phase 1 interventional studies under Infertility, Female, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2025
First posted
Mar 7, 2025
StartActual
Apr 6, 2025
Primary completionActual
Feb 4, 2026
CompletionEst.
Apr 2026
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06864793
Responsible party
Sponsor
First posted
Mar 7, 2025
Start date
Apr 6, 2025
Primary completion
Feb 4, 2026
Completion
Apr 2026 (estimated)
Last update
Feb 17, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin alfa

Start the discussion